Dissemination of the Omicron Variant and Its Sub-Lineages among Residents and Travelers in Its First Year of Emergence in Venezuela.

The emergence of the SARS-CoV-2 Variant of Concern (VOC), Omicron, has been characterized by an explosive number of cases in almost every part of the world. The dissemination of different sub-lineages and recombinant genomes also led to several posterior waves in many countries. The circulation of this VOC and its major sub-lineages (BA.1 to BA.5) was monitored in community cases and in international travelers returning to Venezuela by a rapid partial sequencing method. The specific sub-lineage assignment was performed by complete genome sequencing. Epidemic waves of SARS-CoV-2 cases were observed among international travelers during 2022, a situation not seen before December 2021. The succession of the Omicron VOC sub-lineages BA.1 to BA.5 occurred sequentially, except for BA.3, which was almost not detected. However, the sub-lineages generally circulated two months earlier in international travelers than in community cases. The diversity of Omicron sub-lineages found in international travelers was related to the one found in the USA, consistent with the most frequent destination of international travel from Venezuela this year. These differences are compatible with the delay observed sometimes in Latin American countries in the circulation of the different lineages of the Omicron VOC. Once the sub-lineages were introduced in the country, community transmission was responsible for generating a characteristic distribution of them, with a predominance of sub-lineages not necessarily similar to the one observed in travelers or neighboring countries.

Description of a One-Year Succession of Variants of Interest and Concern of SARS-CoV-2 in Venezuela.

Some of the lineages of SARS-CoV-2, the new coronavirus responsible for COVID-19, exhibit higher transmissibility or partial resistance to antibody-mediated neutralization and were designated by WHO as Variants of Interests (VOIs) or Concern (VOCs). The aim of this study was to monitor the dissemination of VOIs and VOCs in Venezuela from March 2021 to February 2022. A 614 nt genomic fragment was sequenced for the detection of some relevant mutations of these variants. Their presence was confirmed by complete genome sequencing, with a correlation higher than 99% between both methodologies. After the introduction of the Gamma VOC since the beginning of the year 2021, the variants Alpha VOC and Lambda VOI were detected as early as March 2021, at a very low frequency. In contrast, the Mu VOI, detected in May 2021, was able to circulate throughout the country. After the detection of the Delta VOC in June 2021, it became the predominant circulating variant. With the arrival of the Omicron VOC in December, this variant was able to displace the Delta one in less than one month.

Detection of the Omicron variant of SARS-CoV-2 in international travelers returning to Venezuela.

BACKGROUND: By the end of 2021, the SARS-CoV-2 Variant of Concern (VOC) Delta was predominant in most of the world. At the end of November, the Omicron variant was first detected in South Africa. This variant was immediately classified as VOC, due to the explosive increase of cases in South Africa, and the great number of mutations exhibited by this new lineage. Since then, Omicron VOC displaced Delta one in almost every country. Venezuela implemented in May 2021 molecular testing of all the passengers arriving at Venezuelan airports. METHODS: In this study, we analyzed the presence of variants of SARS-CoV-2 in those positive samples, by sequencing a small fragment of the Spike genomic region. RESULTS: The Omicron variant was found in passengers arriving to Venezuela from the beginning of December. Complete genome analysis confirmed the presence of the Omicron VOC. The detection of this VOC coincided with an unprecedented increase in the frequency of passengers with positive nucleic acid testing. CONCLUSIONS: Genomic surveillance of samples for international travelers returning to Venezuela allowed us to rapidly detect the introduction of the Omicron variant in the country.

First Case of Monkeypox in Venezuela: Partial Complete Genome Sequence Allowed Its Grouping into the West African Clade II.

The ongoing epidemic of monkeypox virus (MPXV) infection has already reached more than 50,000 persons worldwide until the end of August 2022. We report the first case detected in Venezuela. The patient reported traveling from Spain and contact with friends tested positive for MPXV after his return. Partial complete genome phylogenetic analysis allowed to group the isolate within the clade II of MPXV, the major one circulating worldwide. No other case of MPXV has been detected until the end of August 2022 in the country, although the presence of undiagnosed cases due to the fear of stigmatization cannot be ruled out.

Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela.

In less than two years since SARS-CoV-2 emerged, the new coronavirus responsible for COVID-19, has accumulated a great number of mutations. Many of these mutations are located in the Spike protein and some of them confer to the virus higher transmissibility or partial resistance to antibody mediated neutralization. Viral variants with such confirmed abilities are designated by WHO as Variants of Concern (VOCs). The aim of this study was to monitor the introduction of variants and VOCs in Venezuela. A small fragment of the viral genome was sequenced for the detection of the most relevant mutations found in VOCs. This approach allowed the detection of Gamma VOC. Its presence was confirmed by complete genome sequencing. The Gamma VOC was detected in Venezuela since January 2021, and in March 2021 was predominant in the East and Central side of the country, representing more than 95% of cases sequenced in all the country in April-May 2021. In addition to the Gamma VOC, other isolates carrying the mutation E484K were also detected. The frequency of this mutation has been increasing worldwide, as shown in a survey of sequences carrying E484K mutation in GISAID, and was detected in Venezuela in many probable cases of reinfection. Complete genome sequencing of these cases allowed us to identify E484K mutation in association with Gamma VOC and other lineages. In conclusion, the strategy adopted in this study is suitable for genomic surveillance of variants for countries lacking robust genome sequencing capacities. In the period studied, Gamma VOC seems to have rapidly become the dominant variant throughout the country.

SARS-CoV-2 genetic diversity in Venezuela: Predominance of D614G variants and analysis of one outbreak.

SARS-CoV-2 is the new coronavirus responsible for COVID-19 disease. The first two cases of COVID-19 were detected in Venezuela on March 13, 2020. The aim of this study was the genetic characterization of Venezuelan SARS-CoV-2 isolates. A total of 7 full SARS-CoV-2 genome sequences were obtained by Sanger sequencing, from patients of different regions of Venezuela, mainly from the beginning of the epidemic. Ten out of 11 isolates (6 complete genomes and 4 partial spike genomic regions) belonged to lineage B, bearing the D614G mutation in the Spike protein. Isolates from the first outbreak that occurred in the Margarita Island harbored an in-frame deletion in its sequence, without amino acids 83-85 of the NSP1 of the ORF1. The search for deletions in 48,635 sequences showed that the NSP1 gene exhibit the highest frequency of deletions along the whole genome. Structural analysis suggests a change in the N-terminal domain with the presence of this deletion. In contrast, isolates circulating later in this island lacked the deletion, suggesting new introductions to the island after this first outbreak. In conclusion, a high diversity of SARS-CoV-2 isolates were found circulating in Venezuela, with predominance of the D614G mutation. The first small outbreak in Margarita Island seemed to be associated with a strain carrying a small deletion in the NSP1 protein, but these isolates do not seem to be responsible for the larger outbreak which started in July.

Gerencia de diagnóstico y vigilancia epidemiológica del Instituto Nacional de Higiene "Rafael Rangel": Una década de avances y logros / Diagnostic and epidemiological surveillance management The National Institute of Hygiene "Rafael Rangel": A decade of advances and achievements

Buscando en los registros de las principales actividades de la Gerencia de Diagnóstico y Vigilancia Epidemiológica ha sido difícil elegir entre tantas vivencias, aquellos elementos que marcaron pauta durante la década 2008 ­ 2018. No obstante, es de resaltar que los desafíos afrontados ante la aparición de brotes, epidemias y la primera pandemia del siglo XXI, trajeron consigo un cúmulo de experiencias que se presentan en este artículo. Como centro nacional de referencia en las áreas de Bacteriología, Micología y Virología, continuamos aportando soluciones a la salud pública nacional mediante la actualización profesional de nuestro personal y la formación de la generación de relevo, en la que participan profesionales de excelencia, altamente especializados y sensibilizados con la problemática y los requerimientos de nuestra población. Asimismo, a través de la coordinación, supervisión y evaluación de la Red de laboratorios de salud pública, se contribuye con el fortalecimiento del diagnóstico de enfermedades transmisibles y vigilancia epidemiológica en el país. El trabajo realizado en estos diez años ha sido excelente, crucial y prioritario para enfrentar las emergencias. Debemos seguir trabajando en dos aspectos claves: 1. Mayor integración del laboratorio con el componente epidemiológico y clínico del país para ser más útiles al sistema de salud, y 2. Consolidar la creación del edificio sede del Centro de Diagnóstico de Enfermedades Transmisibles del Instituto Nacional de Higiene "Rafael Rangel" (INHRR), proyecto en el que estamos trabajando con la asesoría de la OPS/OMS.

Looking at the records of the main activities of the Diagnostic and Epidemiological Surveillance Management, it has been difficult to choose between many experiences, those elements that set the standard during the 2008 ­ 2018 decade. However, it is noteworthy that the challenges faced with the emergence of outbreaks, epidemics and the first pandemic of the 21st century, brought with it a wealth of experiences that are presented in this article. As a national reference center in Bacteriology, Mycology and Virology areas, we continue to provide solutions to public health through the professional updating of our staff and formation of the relief generation, in which participate professionals of excellence, highly specialized and sensitized with the problems and requirements of our population. Likewise, through the coordination, supervision and evaluation of the public health laboratories network, it contributes to the strengthening of the communicable diseases diagnosis and epidemiological surveillance in the country. The work done in these ten years has been excellent, crucial and priority to face emergencies. We must continue working on two key aspects: 1. Greater laboratory integration with the epidemiological and clinical component of the country to be more useful to the health system, and 2. Consolidate headquarters building creation of the National Institute of Hygiene "Rafael Rangel" (INHRR) Diagnostic Center for Communicable Diseases, project in which we are working with the PAHO / WHO advice.

Nuevas consideraciones en el diagnóstico de rubéola en mujeres embarazadas: un hallazgo de laboratorio / New considerations in the diagnostic rubella in pregnant: an finding of laboratory

El trabajo se realizó con un paciente femenina de 28 años de edad, con ocho semanas de embarazo, quien a solicitud de perfil prenatal obtiene resultados compatibles con infección actual y acude al Instituto Nacional de Higiene "Rafael Rangel" para estudios confirmatorios. Se procesó por duplicado muestras de la paciente sometidas a diferentes condiciones: 1) muestra fresca tomada en el INH "RR" justo antes de su procesamiento, 2) muestra tomada en el INH "RR" almacenada a 40ºC y procesada posteriormente y 3) muestra original proveniente de laboratorio privado. Se usaron tres ELISAS para el diagnóstico de rubéola, dos de captura de anticuerpo para IgM e IgG en las cuales no se trata la muestra y una ELISA de captura de antígeno que incluye absorción de factor reumatoide e inmunocomplejos previo al procesamiento de la muestra. En todas las muestras biológicas del caso los resultados de IgM fueron negativos, exceptuando el de la muestra 1 procesada sin tratamiento donde el resultado fue de IgM positivo. Las IgG resultaron positivas en todas las muestras biológicas del caso, sin registrar variaciones significativas entre ellas. Al eliminar los interferentes (factor reumatoide e inmunocomplejos) se confirma la presencia de un falso positivo de IgM de rubéola en la muestra 1, descartándose infección reciente por rubéola y infección por la misma a los valores obtenidos en la IgG.